NCT01358669View on ClinicalTrials.gov

Effect of Denosumab on Inflammatory Osteolytic Lesion Activity in Total Hip Arthroplasty

PHASE2CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

December 14, 2011

Primary Completion Date

January 2, 2019

Study Completion Date

December 31, 2021

Conditions

Revision Surgery of Total Hip Arthroplasty

Interventions

DRUG

Denosumab

60mg denosumab by injection as a single dose

OTHER

Placebo

Placebo by injection as a single dose

Trial Locations (1)

S5 7AU

Academic Unit of Bone Metabolism, Sheffield

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Amgen

INDUSTRY

collaborator

University of Sheffield

OTHER

lead

Sheffield Teaching Hospitals NHS Foundation Trust

OTHER